With new data, Exelixis takes another shot at prostate cancer treatment
In 2014, the Bay Area biotech company Exelixis (EXEL) tried to develop a drug for prostate cancer; its clinical trial ended in failure and nearly shut down the company. A second attempt has delivered better, tumor-shrinking results, according to data released Monday, while still leaving some important questions unanswered.
In an interim look at the ongoing study, a combination regimen consisting of Exelixis’ targeted cancer drug Cabometyx and Roche’s checkpoint inhibitor Tecentriq demonstrated a tumor response rate of 32%. The median duration of response was 8.3 months.